VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35-0.09%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put VNRX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 86% over the past year.
View GrowthManagement screens weak on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 5% on a typical day and fell roughly 98% in its worst 12-month stretch.
View RiskVNRX's growth depends on expanding commercial licensing agreements and milestone revenue. Revenue growth has been steady, but recent Q2 results showed a miss, with revenue at $400K against a consensus of $474K. The stock trades at 1.3× price-to-sales, below the peer median of 2.9×. This suggests that the price reflects less growth than expected. If VNRX cuts guidance on the next call, it could significantly impact the stock. Peer multiples imply a price about 69% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. VNRX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering VNRX (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare VNRX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VNRX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put VNRX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Dilution of shares may impact capital allocation strategy.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Expand commercial licensing agreements and milestone revenue
Q2 revenue missed consensus, impacting growth expectations.
Threatens: Expand commercial licensing agreements and milestone revenue
Earnings miss impacts growth and revenue expectations.
Threatens: Expand commercial licensing agreements and milestone revenue
Earnings beat but revenue shortfall impacts growth objectives.
Threatens: Manage operating expenses to improve financial health
Stock offering at discount may strain financial health.
Advances: Increase revenue through strategic partnerships
Public offering supports revenue growth through partnerships.
Advances: Increase revenue through strategic partnerships
300% revenue growth indicates strong market demand.
Advances: Manage operating expenses to improve financial health
Waiver improves financial flexibility and health.